Omid C. Farokhzad

TL;DR: The arsenal of nanocarriers and molecules available for selective tumour targeting, and the challenges in cancer treatment are detailed and emphasized.

TL;DR: Novel engineering approaches are discussed that capitalize on the growing understanding of tumour biology and nano–bio interactions to develop more effective nanotherapeutics for cancer patients.

TL;DR: These factors have been shown to substantially affect the biodistribution and blood circulation half-life of circulating nanoparticles by reducing the level of nonspecific uptake, delaying opsonization, and increasing the extent of tissue specific accumulation.

TL;DR: This work focuses on the application of nanotechnology to drug delivery and highlights several areas of opportunity where current and emerging nanotechnologies could enable entirely novel classes of therapeutics.

TL;DR: In this article, the authors discuss the factors which can influence nanoparticle blood residence time and organ specific accumulation, including interactions with biological barriers and tunable nanoparticle parameters, such as composition, size, core properties, surface modifications (pegylation and surface charge), and targeting ligand functionalization.